Powassan Virus Infection Likely Acquired Through Blood Transfusion Presenting as Encephalitis in a Kidney Transplant Recipient

Author(s):  
Lindsay Taylor ◽  
Taryn Condon ◽  
Eric M Destrampe ◽  
Jennifer A Brown ◽  
Jeanette McGavic ◽  
...  

Abstract A kidney transplant patient without known tick exposure developed encephalitis 3 weeks after transplantation. During the transplant hospitalization, the patient had received a blood transfusion from an asymptomatic donor later discovered to have been infected with Powassan virus. Here, we describe a probable instance of transfusion-transmitted Powassan virus infection.

2018 ◽  
Vol 40 (1) ◽  
pp. 95-97 ◽  
Author(s):  
Ana Raquel Fernandes ◽  
Laila Almeida Viana ◽  
Juliana Busato Mansur ◽  
Mariana de Moraes Françoso ◽  
Daniel Wagner de Castro Lima Santos ◽  
...  

Abstract Histoplasmosis is a fungus infection that mainly affects immunosuppressed patients. The authors present a case of a kidney transplant recipient who developed sepsis-like histoplasmosis, na atypical but severe manifestation of the disease. The fungus was found in blood and in a skin biopsy, and the treatment with liposomal amphotericin resulted in hepatotoxicity.


Author(s):  
Victoria Oakes ◽  
Dinesh Bahl ◽  
Suresh Antony

: Cytomegalovirus (CMV) retinitis in a kidney transplant recipient is a rare illness with only one other reported case in the literature.. We present a case of a 70-year-old kidney transplant recipient female who presented complaining of decreased vision of her right eye. She was diagnosed with CMV retinitis and started on intravenous ganciclovir. After three weeks of therapy, the patient has had no signs of CMV retinitis.. With only one other previous case report of CMV retinitis in a kidney transplant patient, appropriate treatment and predictability of recurrence are unknown.


2020 ◽  
Vol 8 ◽  
pp. 2050313X2095303
Author(s):  
Camille Pennou ◽  
Eileen Javidi ◽  
Julie Lecours ◽  
Annie Bélisle ◽  
Sandra Davar

Trichodysplasia spinulosa is a rare cutaneous disease caused by the trichodysplasia spinulosa–associated polyomavirus. It occurs more frequently in immunocompromised patients, particularly in solid organ transplants. A few successful treatments have been described in the literature. In our report, we present a biopsy-proven trichodysplasia spinulosa case in a kidney transplant recipient who rapidly responded to a reduction of his immunosuppressive therapy.


2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Joanna C. Masters ◽  
Mita M. Shah ◽  
Ashley A. Feist

Purpose. The case of a kidney transplant recipient who experienced a probable drug interaction between sirolimus and ranolazine is reported.Summary. The narrow therapeutic window of immunosuppressive therapy in transplant recipients requires close monitoring for potential drug-drug interactions. The patient, a 57-year-old Caucasian male kidney transplant recipient, was stable for years on sirolimus as his primary immunosuppressive agent and had a history of chronic angina, for which he was prescribed ranolazine. Upon addition and dose escalation of ranolazine, whole blood sirolimus levels more than tripled, rising to immeasurably high concentrations. After holding sirolimus on multiple occasions and reducing dosage more than 50%, blood levels returned to therapeutic range, while continuing ranolazine.Conclusion. Since ranolazine is a documented P-GP and CYP3A inhibitor, and sirolimus a known substrate for both pathways, it is proposed that ranolazine inhibition of P-GP and CYP3A4 contributed to the significant elevation in sirolimus exposure. No alternative causes for the rise in sirolimus exposure were found, and assessment with the Drug Interaction Probability Scale finds this interaction to be probable. Clinicians should be aware of the potential for this interaction to cause elevated sirolimus exposure and subsequent increase in clinical effect or toxicity, in this case overimmunosuppression.


2021 ◽  
pp. 195-203
Author(s):  
Katarzyna Muras-Szwedziak ◽  
Maciej Tylski ◽  
Anna Masajtis-Zagajewska ◽  
Michał Nowicki

Hemophagocytic lymphohistiocytosis (HLH) is an uncommon life-threatening condition caused by an uncontrolled immunological response. It can develop secondary to malignancies, infections, systemic diseases, and immunosuppression. Multiple risk factors may present in kidney transplant recipients; however, the cases of HLH in this population have been described sparsely. We report a case of a 39-year-old female kidney transplant recipient who presented to the hospital nearly 3.5 years after the transplantation with general malaise, recent history of weight loss, fevers, and persistent anemia. Laboratory tests showed pancytopenia, hyperferritinemia, hypertriglyceridemia, and increased activity of lactate dehydrogenase. A bone marrow aspiration revealed hemophagocytosis, which led to the diagnosis of HLH. Therapy consisting of high-dose steroids and plasma exchanges was administered, resulting in a significant improvement of blood count parameters and the patient’s general condition. While searching for the triggering disease, a single cavitary lesion in the right lung was revealed in a chest radiograph. Computed tomography scan, bronchoscopy, and additional laboratory testing did not reveal a definitive cause of the lesion. We suspect that the lesion may be a consequence of HLH. The patient was disqualified from thoracic surgery due to multiple comorbidities. Even though HLH is a rare condition, it should be taken into consideration in a kidney transplant patient presenting with unspecific symptoms accompanied by a bicytopenia. It has an unpredictable course that often results in serious complications. Thus close follow-up of the patient and a wide array of imaging and laboratory tests remain crucial.


2019 ◽  
Vol 7 (5) ◽  
pp. 60
Author(s):  
Kmar Mnif ◽  
Soumaya Yaich ◽  
Fatma Fendri ◽  
Abdelrahmen Masmoudi ◽  
Khaled Charfeddine ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Adnane Guella ◽  
Osman Elfadil ◽  
Ghisson Abdulrazaq ◽  
Sahla Osman ◽  
Mohammed Munir Khan ◽  
...  

The presentation of COVID-19 pneumonia in kidney transplant recipients is similar to that of the general population. However, in the former, it may have a worse clinical course. We report a kidney transplant patient affected by COVID-19 pneumonia whose condition worsened 9 days after the initial presentation. As no therapeutic guidelines on the subject are currently available, here we share our approach in the management of the immunosuppressive medications and the antiviral therapy and compare them to the scarce available data. We also expose the use of tocilizumab in our patient with excellent results.


Sign in / Sign up

Export Citation Format

Share Document